Notably, cyclin-dependent kinase 4/6 (CDK4/6, cell cycle-related genes) inhibitors have shown significant activity against several cancers and some (namely palbociclib, ribociclib and abemaciclib) are approved for treatment of patients with advanced breast cancer (18). Here, CDK4 is linked to breast carcinoma.